78 FR 57 pgs. 17866-17868 - New Animal Drug Approvals; Change of Sponsor; Change of Sponsor's Drug Labeler Code; Gonadorelin Acetate; Isoflurane; Praziquantel; Propofol; Sevoflurane; Triamcinolone Acetonide
Type: RULEVolume: 78Number: 57Pages: 17866 - 17868
Docket number: [Docket No. FDA-2013-N-0002]
FR document: [FR Doc. 2013-06748 Filed 3-22-13; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: Food and Drug Administration
Official PDF Version: PDF Version
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 510, 522, 524, and 529
[Docket No. FDA-2013-N-0002]
New Animal Drug Approvals; Change of Sponsor; Change of Sponsor's Drug Labeler Code; Gonadorelin Acetate; Isoflurane; Praziquantel; Propofol; Sevoflurane; Triamcinolone Acetonide
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Final rule.
SUMMARY:
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during January 2013. FDA is also informing the public of the availability of summaries the basis of approval and of environmental review documents, where applicable. The animal drug regulations are also being amended to reflect changes of sponsorship for an NADA and ANADA, and a change of a sponsor's drug labeler code.
DATES:
This rule is effective March 25, 2013.
FOR FURTHER INFORMATION CONTACT:
George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9019, email: george.haibel@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during January 2013, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents through the Center for Veterinary Medicine's (CVM's) FOIA Electronic Reading Room at http://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CVM/CVMFOIAElectronicReadingRoom/default.htm.
In addition, FDA is amending the animal drug regulations to reflect changes of sponsorship for an NADA and ANADA, and a change of a sponsor's drug labeler code.
RMS Laboratories, Inc., 1903 East First St., Vidalia, GA 30474, has informed FDA that it has transferred ownership of, and all rights and interest in, NADA 141-210 for GENESIS (triamcinolone acetonide) Topical Spray to Virbac AH, Inc., 3200 Meacham Blvd., Ft. Worth, TX 76137. Following this change of sponsorship, RMS Laboratories, Inc., will no longer be the sponsor of an approved application.
Teva Animal Health, Inc., 3915 South 48th Street Ter., St. Joseph, MO 64503, has informed FDA that it has transferred ownership of, and all rights and interest in, ANADA 200-176 for PRAZITECH (praziquantel) Injectable Solution to Cross Vetpharm Group Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland.
Abbott Laboratories, North Chicago, IL 60064, has informed FDA of a change in drug labeler code. Accordingly, the Agency is amending the regulations in 21 CFR 510.600 to reflect this change of drug labeler code and to remove entries for RMS Laboratories, Inc., and in 21 CFR parts 522 and 529 to make conforming changes to Abbott Laboratories' product listings.
This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
| NADA/ANADA | Sponsor | New animal drug product name | Action | 21 CFR Section | FOIA Summary | NEPA Review |
|---|---|---|---|---|---|---|
| 200-541 | Parnell Technologies Pty. Ltd., unit 4, 476 Gardeners Rd., Alexandria, New South Wales 2015, Australia | GONABREED (gonadorelin acetate) Injectable Solution | 1. Original approval as a generic copy of NADA 098-379; and 2. Supplemental approval for use with cloprostenol sodium to synchronize estrous cycles to allow for fixed time artificial insemination in lactating dairy cows and beef cows.1 | 522.1073 | yes | 1. CE2 2. EA/FONSI3 |
| 1 Supplemental approval under section 512(b)(1) of the Federal Food, Drug, and Cosmetic Act. | ||||||
| 2 The Agency has determined under 21 CFR 25.33 that this action is categorically excluded (CE) from the requirement to submit an environmental assessment (EA) or an environmental impact statement (EIS) because it is of a type that does not individually or cumulatively have a significant effect on the human environment. | ||||||
| 3 Based on its review of an EA submitted by the sponsor, the Agency has concluded that this action will not have a significant impact on the human environment and that an EIS is not required. A finding of no significant impact (FONSI) has been prepared. | ||||||
List of Subjects
21 CFR Part 510
Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.
21 CFR Parts 522, 524, and 529
Animal drugs.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 522, 524, and 529 are amended as follows:
PART 510-NEW ANIMAL DRUGS
1. The authority citation for 21 CFR part 510 continues to read as follows:
Authority:
21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.
2. Amend § 510.600 as follows:
a. In the table in paragraph (c)(1), revise the entry for "Abbott Laboratories" and remove the entry for "RMS Laboratories, Inc."; and
b. In the table in paragraph (c)(2), remove the entries for "000074" and "067292" and add an entry for "000044" in numerical order.
The addition and revision read as follows:
§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.
(c) * * *
(1) * * *
| Firm name and address | Drug labeler code |
|---|---|
| ***** | |
| Abbott Laboratories, North Chicago, IL 60064 | 000044 |
| ***** |
(2) * * *
| Drug labeler code | Firm name and address |
|---|---|
| ***** | |
| 000044 | Abbott Laboratories, North Chicago, IL 60064. |
| ***** |
PART 522-IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS
3. The authority citation for 21 CFR part 522 continues to read as follows:
Authority:
21 U.S.C. 360b.
4. Add § 522.1073 to read as follows:
§ 522.1073 Gonadorelin acetate.
(a) Specifications. Each milliliter of solution contains 100 micrograms (µg) of gonadorelin as gonadorelin acetate.
(b) Sponsor. See No. 068504 in § 510.600(c) of this chapter.
(c) Conditions of use in cattle- (1) Indications for use and amounts.
(i) For the treatment of ovarian follicular cysts in dairy cattle. Administer 100 µg gonadorelin by intramuscular or intravenous injection.
(ii) For use with cloprostenol sodium to synchronize estrous cycles to allow for fixed-time artificial insemination in lactating dairy cows and beef cows. Administer to each cow 100 µg gonadorelin by intramuscular injection, followed 6 to 8 days later by 500 µg cloprostenol by intramuscular injection, followed 30 to 72 hours later by 100 µg gonadorelin by intramuscular injection.
(2) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
5. In § 522.1077, revise the section heading to read as set forth below; and in paragraph (c)(3), remove the first sentence.
§ 522.1077 Gonadorelin hydrochloride.
§ 522.1078 [Redesignated as § 522.1075]
6. Redesignate § 522.1078 as § 522.1075.
7. In § 522.1870, revise the section heading and paragraphs (b), (c)(1)(iii), and (c)(2)(iii) to read as follows:
§ 522.1870 Praziquantel.
(b) Sponsors. See Nos. 000859 and 061623 in § 510.600(c) of this chapter.
(c) * * *
(1) * * *
(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(2) * * *
(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 522.2005 [Amended]
8. In paragraph (b)(2) of § 522.2005, remove "000074" and in its place add "000044".
PART 524-OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS
9. The authority citation for 21 CFR part 524 continues to read as follows:
Authority:
21 U.S.C. 360b.
§ 524.2482 [Amended]
10. In paragraph (b) of § 524.2482, remove "067292" and in its place add "051311".
PART 529-CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS
11. The authority citation for 21 CFR part 529 continues to read as follows:
Authority:
21 U.S.C. 360b.
§ 529.1186 [Amended]
12. In paragraph (b) of § 529.1186, remove "000074" and in its place add "000044".
§ 529.2150 [Amended]
13. In paragraph (b) of § 529.2150, remove "000074" and in its place add "000044".
Dated: March 20, 2013.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2013-06748 Filed 3-22-13; 8:45 am]
BILLING CODE 4160-01-P